GlassScriptPhysician profile
Steven A Madden
NPI 1538198171
$3,268.32
in general payments reported to CMS, 2019-2025
47 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $38.70 · 2021: $45.93 · 2022: $47.04 · 2023: $509 · 2024: $816 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.82 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $402.93 | 2023-2025 | |
| Pfizer INC. | $259.82 | 2023-2025 | |
| Celgene Corporation | $213.23 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $189.17 | 2024-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $176.77 | 2024-2025 | Darzalex, Tecvayli, Erleada |
| Daiichi Sankyo INC. | $161.16 | 2019-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $149.36 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $142.94 | 2023-2025 | Monjuvi, Pemazyre, Zynyz |
| Amgen INC. | $138.32 | 2019 | |
| Genentech USA, INC. | $130.33 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Abbvie INC. | $127.91 | 2023-2025 | |
| Gilead Sciences, INC. | $125.92 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $74.78 | 2019-2024 | Lynparza |
| Genzyme Corporation | $71.99 | 2023-2024 | |
| Medtronic USA, INC. | $60.86 | 2019-2020 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $60.04 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $51.38 | 2021-2024 | Libtayo |
| Stemline Therapeutics INC. | $50.39 | 2024-2025 | Orserdu |
| Emd Serono, INC. | $49.75 | 2023-2025 | Bavencio |
| Array Biopharma INC | $47.92 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Astellas Pharma US INC | $37.78 | 2024-2025 | Vyloy, Padcev |
| Glaxosmithkline, LLC. | $36.11 | 2025 | Ojjaara |
| Kyowa Kirin, INC. | $31.06 | 2019-2025 | |
| Seagen INC. | $30.51 | 2023 | Tukysa, Adcetris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.94 | 2025 | |
| Novocure INC. | $26.64 | 2023 | Optune |
| Eisai INC. | $24.25 | 2024 | |
| Sobi, INC | $23.15 | 2025 | |
| Kite Pharma, INC. | $22.60 | 2025 | Yescarta |
| Exelixis INC. | $22.60 | 2020 | |
| Aveo Pharmaceuticals, INC. | $22.39 | 2025 | |
| Morphosys, US INC. | $22.25 | 2023 | Monjuvi |
| Genmab U.S., INC. | $22.20 | 2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $20.53 | 2024 | Ultomiris |
| Pharmaessentia USA Corporation | $20.36 | 2025 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $20.22 | 2023 | Epkinly, Imbruvica |
| Rigel Pharmaceuticals, INC. | $20.21 | 2023 | Tavalisse, Rezlidhia |
| Adc Therapeutics America, INC. | $19.36 | 2025 | |
| Taiho Oncology, INC. | $18.91 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $18.86 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.48 | 2023 | Odomzo, Yonsa |
| Jazz Pharmaceuticals INC. | $17.60 | 2023 | |
| Tempus Ai, INC | $16.70 | 2025 | Xt Cdx |
| Springworks Therapeutics, INC. | $15.31 | 2025 | Ogsiveo |
| Mirati Therapeutics, INC. | $14.13 | 2024 | Krazati |
| Mylan Institutional INC. | $13.20 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Madden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.